Clinical performance, in the context of an in vitro diagnostic, refers to the ability to deliver results that correlate with a specific clinical condition or a physiological or pathological process in the target population and with the intended user. Alongside scientific validity and analytical performance, it is an element of performance evaluation under the IVDR. Clinical performance thus answers whether the test result is medically meaningful.
Position within Performance Evaluation
Performance evaluation examines and documents the scientific validity, analytical performance, and, where applicable, the clinical performance of an IVD. Scientific validity describes the association between the analyte and the clinical condition. Analytical performance, by contrast, concerns whether the system can technically measure or detect the analyte correctly. Clinical performance links the generated result to the intended medical statement.
Which data are required depends on the intended purpose, target population, user, risk, and state of the art. For a diagnostic test, for example, diagnostic sensitivity, diagnostic specificity, positive or negative predictive values, and expected values in healthy or affected populations may be relevant. The selection must explain which medical decision the product is intended to support.
Data Sources and Clinical Performance Studies
Clinical performance may be demonstrated through clinical performance studies, scientific literature, or published experience from routine use. A clinical performance study is conducted to establish or confirm the clinical performance of an IVD. It becomes necessary when existing data do not adequately support the specific clinical claim or when a study is objectively warranted over other sources.
The Performance Evaluation Plan specifies which data are collected, evaluated, and continuously updated. Study endpoints must be aligned with the claimed correlation, not solely with technical measurement accuracy. Sample origin, reference method, target population, and intended user influence whether results are transferable to the intended purpose.
Clinical performance is not determined in isolation from the intended context of use. A marker may reliably correlate with a disease state in specialised laboratories, with a specific sample matrix, and in a narrowly defined target group, without that claim applying equally to point-of-care users or a screening population. The evidence must therefore reflect the conditions under which the test is to be marketed.
For multiparametric or software-supported IVDs, it is also necessary to describe how the combination of measured values leads to the clinical statement. A correct individual measurement does not automatically prove the clinical performance of an algorithm or a classification score. Performance evaluation requires a traceable connection between output, reference condition, and medical interpretation.
The clinical performance claim should therefore extend only as far as the evidence supports the correlation for the defined indication. A result for disease monitoring cannot be used as evidence for screening or therapy selection without additional supporting data. The claim remains tied to population, sample, and use.
Distinction from Clinical Benefit in Medicinal Products
The clinical benefit of an IVD consists in delivering accurate medical information. The test result may support diagnosis, triage, therapy selection, or disease monitoring, but does not itself produce the treatment outcome. Between the result and the health status lie further steps such as clinical interpretation, confirmatory testing, and therapeutic decision-making.
The concept of benefit thus differs fundamentally from medicinal products, where the therapeutic effect on the patient is central. An IVD may be clinically performant even though treatment success arises only from the interplay of test, clinical decision, and care. The evaluation must not attribute these downstream factors to the test as its own effect.
Relevance for clinical trials
For a clinical performance study, the intended purpose and medical question must be translated into precise endpoints. What is decisive is which samples and which patient population represent the claimed use, against which clinical reference condition comparison is made, and how inconclusive results are handled. A study that merely confirms analytical performance cannot replace the required clinical correlation.
Full-service CROs such as Mediconomics support the planning of clinical performance studies, the definition of reference procedures, and the organisation of sample and data flows between laboratory and investigational site. They accompany data management, biostatistics, and medical writing for the Performance Evaluation Plan and Performance Evaluation Report, ensuring that clinical parameters are traceable to the intended purpose of the IVD.
Frequently Asked Questions (FAQ)
Is clinical performance the same as analytical performance?
No. Analytical performance concerns the technical ability to generate a correct measurement or detection result; clinical performance concerns its correlation with a clinical condition or process.
When does an IVD require a clinical performance study?
It must be conducted when clinical performance cannot be adequately demonstrated by other means or when no sound justification exists for relying on other data sources.
Does a positive test result already demonstrate therapeutic benefit?
No. The result provides medical information; the therapeutic effect depends on subsequent clinical decisions and treatment measures.
Regulatory References
- Regulation (EU) 2017/746, Article 2(41) – defines the clinical performance of IVDs.
- Regulation (EU) 2017/746, Annex XIII – governs performance evaluation and clinical evidence.
- MDCG 2022-2 – explains the principles of clinical evidence for IVDs.
- MDCG 2025-5 – describes performance studies for confirming analytical or clinical performance.